Annovis

Annovis Bio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update See more here

Annovis Bio Announces Approval for European Union Clinical Trial Sites for the Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease The Company was Granted Approval for an Additional 48 sites Across Five European Union Countries Annovis Currently has 50 Clinical Trial Sites Open in the United States…

Annovis Bio Announces Filing of Patent Covering the Administration of Buntanetap and Its Analogues for the Treatment of Mental Illnesses See more here

Annovis Bio Announces Patient Enrollment Update For Phase 3 Study of Buntanetap for the Treatment of Parkinson's Disease Strong enrollment in Phase 3 trial demonstrates continued execution Interim analysis expected in 2Q 2023 See more here

Annovis Bio Announces New Appointments to Strengthen Its Senior Leadership Team See more here

Annovis Bio Announces Third Quarter 2022 Results and Provides Corporate Update See more here

Annovis Bio Announces Publication of Phase 2a Clinical Data in The Journal of Prevention of Alzheimer's Disease See more here

Annovis Bio Announces FDA Authorization to Proceed with Phase 2/3 Trial for Buntanetap in Alzheimer's Disease See more here

Annovis Bio Announces Publication of Patents Covering the Treatment of Amyloid Lateral Sclerosis, Huntington's Disease and Prion Diseases See more here

Annovis Bio Appoints Henry Hagopian III as Chief Financial Officer See more here